{
  "id": "643def7057b1c7a31500003a",
  "type": "summary",
  "question": "What does mitapivat do?",
  "ideal_answer": "Mitapivat is an oral drug that activates the pyruvate kinase enzyme, increasing ATP production and reducing levels of 2,3-diphosphoglycerate. It is used for the treatment of hereditary hemolytic anemias",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
    "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
    "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
    "http://www.ncbi.nlm.nih.gov/pubmed/34889443",
    "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
    "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
    "http://www.ncbi.nlm.nih.gov/pubmed/36124781",
    "http://www.ncbi.nlm.nih.gov/pubmed/31974203",
    "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
    "http://www.ncbi.nlm.nih.gov/pubmed/31483964"
  ],
  "snippets": [
    {
      "text": "Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.METHODS: In this global, phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of mitapivat in adults with pyruvate kinase deficiency who were not receiving regular r",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974203",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Mitapivat, a pyruvate kinase activator, represents a unique mechanism to mitigate ineffective erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34889443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RT OPINION: Mitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}